(Columbia) April 11, 2003 - Catherine Price is a natural on the piano. She has Type One diabetes, but doesn't let it slow her down. She keeps her disease in tight control, "It's a tightrope and if you're off on either side, there are consequences."
Catherine has it better than many diabetics, thanks to a two-week experimental treatment she received shortly after diagnosis. Kevan Herold and endocrinologist with Columbia Presbyterian Medical Center in New York and says HOKT3 Gamma-1 is the first short-term therapy that appears to slow progression of the disease, "We know that it inactivates the cells that are responsible for the development of Type 1 diabetes. So somehow or another, it turns them off so that they don't continue to destroy the insulin-producing cells."
While it's unclear how long the effects will last, Herold says two years later Catherine is producing more of her own insulin than she probably would have without the treatment, "People who control their diabetes very well will have a much lower risk of developing the long-term complications, such as eye disease, kidney disease and others. And if you're able to make some of your own insulin, it's a lot easier to do that."
Researchers are conducting additional studies to see if HOKT3 Gamma might also be effective in treating people who've had Type One diabetes longer and also in delaying the onset of the disease.
WISTV License Subsidiary, LCC
1111 Bull St.